ORIGINAL

Influence of tobacco consumption on the values of different overweight and obesity scales in 418,343 spanish people

Influencia del consumo de tabaco en los valores de diferentes escalas de sobrepeso y obesidad en 418.343 españoles

Miguel Carlos Aguiló Juanola¹, Ángel Arturo López-González² Pilar Tomás-Gil², Hernán Paublini², Pedro J. Tárraga López⁵, José Ignacio Ramírez-Manent^{2,3,4}

 Community Pharmacist
 ADEMA-Health group IUNICS University of the Balearic Islands, Spain 3. Mallorca Primary Care
 Faculty of Medicine, University of the Balearic Islands
 Faculty of Medicine, University of Castilla la Mancha

Corresponding author

Ángel Arturo López-González E-mail: angarturo@gmail.com Received: 20 - VII - 2023 Accepted: 23 - VIII - 2023

doi: 10.3306/AJHS.2023.38.06.111

Summary

Introduction and objectives: Both obesity and smoking can be considered pandemics due to their high prevalence worldwide. The aim of this study was to assess the effect of tobacco consumption and other sociodemographic variables such as sex, age, and social class on the prevalence of obesity assessed with different scales.

Material and methods: Descriptive, cross-sectional study carried out in 418343 Spanish workers in whom excess weight was assessed by applying different scales such as BMI, waist/height index, body fat estimators such as CUN BAE, and visceral fat estimators such as METS-VF, among others. The influence of sociodemographic variables (age, sex, and social class) and tobacco consumption on the prevalence of overweight and obesity was also assessed.

Results: Being male, being older, belonging to a more disadvantaged social class (social class III), and being a smoker increased the risk of presenting high values in the different scales that assess excess weight.

Conclusions: Both sociodemographic variables and tobacco consumption influence the prevalence of obesity determined with different scales; in the case of tobacco, this relationship is not observed if BRI and METS-VF are used.

Key words: Obesity, overweight, tobacco, sociodemographic variables.

Resumen

Introducción y objetivos: Tanto la obesidad como el tabaquismo pueden ser consideradas como pandemias debido a su alta prevalencia en todo el mundo. El objetivo de este estudio es valorar el efecto del consumo de tabaco y otras variables sociodemográficas como sexo, edad y clase social en la prevalencia de obesidad valorada con diferentes escalas.

Material y métodos: Estudio descriptivo y transversal realizado en 418.343 trabajadores españoles en el que se valora el exceso de peso aplicando diferentes escalas como IMC, índice cintura/altura, estimadores de grasa corporal como CUN BAE y estimadores de grasa visceral como METS-VF entre otros. Se valora también la influencia de variables sociodemográficas (edad, sexo y clase social) y el consumo de tabaco en la prevalencia de sobrepeso y obesidad.

Resultados: Ser varón, tener edad avanzada, pertenecer a una clase social más desfavorecida (clase social III) y ser fumador incrementan el riesgo de presentar valores altos de las diferentes escalas que valoran el exceso de peso.

Conclusiones: Tanto las variables sociodemográficas como el consumo de tabaco influyen en la prevalencia de obesidad determinada con diferentes escalas, en el caso del tabaco esta relación no se aprecia si empleamos BRI y METS-VF.

Palabras clave: Obesidad, sobrepeso, tabaco, variables sociodemográficas.

Cite as: Aguiló Juanola MC, López-González AA, Tomás-Gil P, Paublini H, Tárraga-López PJ, Ramírez-Manent JI. Influence of tobacco consumption on the values of different overweight and obesity scales in 418,343 spanish people. *Academic Journal of Health Sciences 2023*; 38 (6):111-7 doi: 10.3306/AJHS.2023.38.06.111

Introduction

Obesity is currently considered a pandemic¹ responsible for or favoring different pathologies, whether cardiovascular², metabolic³, musculoskeletal⁴, gastrointestinal⁵, or psychological⁶.

The body mass index (BMI), which is a simple indicator of the relationship between weight and height, is frequently used to identify adults who are overweight or obese. For its calculation, a person's weight in kilograms is divided by the square of his or her height in meters (kg/m²). However, although this indicator is the most commonly used, there are other scales for assessing excess weight, some of which are based on anthropometric parameters such as waist circumference or the waist/height index; others are based on estimates of body fat, such as the Clínica Universitaria de Navarra body fat estimator (CUN BAE)⁷; or on estimators of visceral fat, such as the Metabolic Score for Visceral Fat (METS-VF)⁸.

Smoking is one of the most prevalent addictions worldwide and is responsible for a multitude of pathologies, including respiratory⁹, cardiovascular¹⁰, gastric¹¹, and oncologic¹², among others.

The aim of this study was to assess the effect of tobacco consumption on excess weight as determined by different scales in a Spanish working population.

Figure 1: Flowchart.



Methods

During the period from January 2017 to December 2019, a descriptive, cross-sectional study was conducted on 418,343 Spanish workers from various regions and productive sectors. The individuals were chosen from among those who underwent regular health examinations in the various participating companies.

The following were the requirements to be included in the study: being between 18 and 69 years of age, working for a company included in the study, not being temporarily incapacitated, and having signed the informed consent to participate in the study and to use their data for epidemiological purposes.

The characteristics of the population are shown in **table I**, with all anthropometric, clinical, and analytical variables showing higher or less favorable values in men. The most common age group was between 30 and 49 years. Most of the employees had only primary education and belonged to social class III. About one in three people who participated in the study smoked.

Measurement and data collection

After standardization of the measurement techniques, the health professionals of the companies participating in the study performed clinical and analytical anthropometric measurements (height, weight, and waist circumference).

A SECA 700 measuring scale was used to measure weight (in kg) and height (in cm). With the person standing, feet together, trunk erect, and abdomen relaxed, a SECA tape measure was used to measure waist circumference. At the height of the final floating rib, the tape was placed parallel to the ground.

A calibrated OMRON M3 automatic sphygmomanometer was used to measure blood pressure in a seated position after a 10-minute rest. Three determinations were made one minute apart, and the mean of each was recorded. After 12 hours of fasting, the analytical parameters were acquired. Glycemia, total cholesterol, and triglycerides were obtained using automated enzymatic methods, while HDL-c was obtained using a precipitation process with dextran sulfate-MgCl2. Friedewald's formula was used to indirectly calculate LDL-c. All analytical parameters were expressed in milligrams per deciliter.

Friedewald's Formula: LDL = total cholesterol – HDL – triglycerides /5

The following were used as scales for overweight and obesity:

- Body mass index (BMI): weight (kg)/height² (cm). Obesity as from 30 kg/m²
- Modified BMI: 1.3 x weight(kg)/height(m)^{2.5}

- Triponderal index: weight (kg)/height³ (cm).
- Waist-to-height ratio: High values from 0.50.
- CUN BAE (Clínica Universitaria de Navarra body adiposity estimator)¹³
 - -44.988+(0.503×age) +(10.689 ×sex) +(3.172 ×IMC) -(0.026 ×IMC2) +(0.181 ×IMC ×sex) -(0.02 ×IMC ×age) -(0.005 ×IMC2 ×sex) +(0.00021 ×IMC2 ×age), where males=0 and females=1 Obesity >25% males and >35% females.
- ECORE-BF (Equation Cordoba estimator body fat)¹⁴
 97.102 + 0.123 x age + 11.9 x sex + (35.959 x Ln(BMI) where males=0 and females=1 Obesity
 >25% males and >35% females
- RFM (Relative Fat Mass)¹⁵.
- RFM women= 76 20 x (height/waist circumference)
- RFM men = 64- 20 x (height/waist circumference)
- Obesity ≥ 40% women ≥ 30% men
- Deurenberg formula¹⁶ (1.2 x BMI) + (0.23 x age)-(10.8 x sex)-5.4 men=0 women=1 Obesity >25% men >32% women
- Palafolls formula¹⁷ men = (BMI/waist circumference) \times 10) + BMI women = (BMI/waist circumference) \times 10) + BMI + 10 Obesity >25% men >32% women
- Metabolic score for visceral fat (METS-VF)¹⁸
 4.466 + 0.011*(Ln(METS-IR))3 + 3.239*(Ln(waist/height))3 + 0.319*(Sex) + 0.594*(Ln(age)). 1 =
 men 0 = women. High values ≥ 7,2
 METS-IR¹⁹ = Ln (2 x glycemia + triglycerides) x
 BMI/Ln (HDL)
- Body Surface index (BSI)²⁰
 Body Surface area (BSA) = weight^{0,425} x height^{0,725} x 0,0007184 BSI = weight/√BSA
 normalized Weight-adjusted index (NWAI)²¹ (weight/10) (10 x height) + 10
- Body shape index (ABSI)²² Waist/(BMI^{2/3} x height^{1/2})
- Body roundness index (BRI)²³ 364.2-365.5 x $\sqrt{1-((waist/2\Pi)^2)/(0.5 \text{ height})^2)}$
- Visceral adiposity index (VAI)²⁴
 Men (Waist/39.68 + (1.88 x BMI)) x (triglycerides/1.03) x (1.31/HDL)
 Women (Waist/36.58 + (1.89 x BMI)) x (triglycerides/0.81) x (1.52/HDL)
- Dysfunctional adiposity index (DAI)²⁵ Men(Waist/2.79+(2.68×BMI))×(triglycerides/1.37) x (1.19/HDL) Women (Waist/24.02 + (2.37 x BMI)) x (triglycerides/1.32) x (1.43/HDL)

- Conicity index²⁶
- (Waist (m)/0.109) $\times 1/\sqrt{\text{weight (kg)/height (m)}}$.
- Waist weight index (WWI)²⁷ waist/height^{1/2}

Smokers were those who had smoked at least one cigarette a day (or its equivalent in other types of consumption) in the previous 30 days or had stopped smoking less than a year before.

Three categories of social classes were created based on profession and the proposal of the social determinants group of the Spanish Society of Epidemiology²⁸, which established three categories: Class I includes directors and managers, sportsmen and artists, university professionals, and skilled self-employed workers. Class II includes intermediate occupations and unskilled selfemployed workers. Class III includes unskilled workers.

Statistical analysis

A descriptive analysis of the categorical variables was performed, by calculating their frequency and distribution. Since the variables had a normal distribution, the mean and standard deviation were calculated for the quantitative variables.

Student's t-test for independent samples and the Chisquared test for independent samples were used. Fisher's exact statistic was corrected when conditions required it. Multivariate analysis was carried out using multinomial logistic regression, calculating odds ratios with 95% confidence intervals. The Statistical Package for the Social Sciences (SPSS) version 28.0 for Windows was used for the statistical analysis, with an accepted statistical significance level of 0.05.

Ethical considerations

The research team undertook at all times to comply with the ethical standards for research in health sciences established nationally and internationally (Declaration of Helsinki), paying special attention to the anonymity of the participants and the confidentiality of the data collected. The Ethics and Research Committee of the Balearic Islands (CEI-IB) approved the study with indicator IB 4383/20. As participation in the study was voluntary, participants gave their consent, both oral and written, after having received sufficient information regarding the nature of the study. To achieve this, they were given an informed consent form together with an information sheet with an explanation of the study aim.

A code was used to identify the study data, and only the person in charge is able to relate these to the participants. No report of this study will reveal the identity of the participants. The investigators will avoid disseminating any information that identifies them. In any case, the research team is committed to complying with Table I: Characteristics of the population.

Organic Law 3/2018, of December 5, on the protection of personal data and guarantee of digital rights, ensuring that study participants have the right to access, rectify, cancel, and oppose the data collected.

Results

The anthropometric and clinical characteristics of the 418343 workers participating in the study (246061 men, and 172282 women) are shown in **table I**. Most of the participants in the group were between 30 and 49 years old, with a mean age of 40.2 ± 11.0 years. In men, all variables

showed more negative values. One out of three workers smoked, and three out of four were from social class III.

Table II shows the mean values of several scales to assess overweight and obesity. It can be observed that in the group of smokers, both men and women, all the scales analyzed show higher values. In all situations, the variations detected were statistically significant.

Table III shows the prevalence of high values in all the overweight and obesity assessment scales. Smokers of both sexes had higher values than non-smokers. In this case, the variations observed were also statistically significant.

Women Men Total n=172.282 n=246.061 n=418.343 Mean (SD) Mean (SD) Mean (SD) p-value Age 39.6 (10.8) 40.6 (11.1) 40.2 (11.0) < 0.0001 Height 161.8 (6.5) 174.6 (7.0) 169.4 (9.3) < 0.0001 Weight 66.2 (14.0) 81.4 (14.7) 75.1 (16.2) < 0.0001 < 0.0001 Waist 74.8 (10.6) 86.2 (11.1) 81.5 (12.2) SBP 117.4 (15.7) 128.2 (15.5) 123.7 (16.5) < 0.0001 DBP 72.6 (10.4) 77.8 (11.0) 75.6 (11.0) < 0.0001 Cholesterol 190.6 (35.8) 192.6 (38.9) 191.8 (37.7) < 0.0001 50.3 (8.5) < 0.0001 HDL-c 56.8 (8.7) 53.0 (9.1) < 0.0001 LDL-c 116.1 (34.8) 118.0 (36.7) 117.2 (35.9) Triglycerides 89.1 (46.2) 123.7 (86.4) 109.5 (74.6) < 0.0001 Glycemia 87.8 (15.1) 93.3 (21.3) 91.0 (19.2) < 0.0001 % p-value % % 18-29 years 20.7 18.8 19.6 < 0.0001 30-39 years 29.7 27.6 28.4 40-49 years 30.0 29.6 29.9 50-59 years 16.8 19.7 18.5 >60 years 3.2 3.9 3.6 Social class I 6.9 4.9 5.7 < 0.0001 Social class II 23.4 14.9 18.4 Social class III 69.7 80.3 75.9 Non-smokers 67.2 66.6 66.9 < 0.0001 Smokers 32.8 33.4 33.2

Table II: Mean values of the different indicators of overweight and obesity according to tobacco consumption by sex.

	Men			Women			
	Non-smokers n=163920 Mean (SD)	Smokers n=82141 Mean (SD)	p-value	Non-smokers n=115727 Mean (SD)	Smokers n=56555 Mean (SD)	p-value	
Body mass index	26.6 (4.5)	26.9 (4.5)	0.087	25.3 (5.2)	25.6 (5.1)	<0.001	
Body mass index modified	26.3 (4.5)	26.5 (4.5)	< 0.001	25.9 (5.4)	26.2 (5.3)	<0.001	
Triponderal index	15.3 (2.7)	15.5 (2.7)	< 0.001	15.7 (3.3)	15.9 (3.3)	<0.001	
Waist to height ratio	0.49 (0.06)	0.49 (0.06)	0.004	0.46 (0.06)	0.46 (0.06)	0.003	
CUN BAE	25.6 (6.6)	25.8 (6.6)	< 0.001	35.3 (7.1)	35.7 (7.1)	<0.001	
ECORE-BF	25.6 (6.3)	25.9 (6.3)	< 0.001	35.2 (7.3)	35.7 (7.3)	<0.001	
Relative fat mass	22.5 (5.0)	22.8 (5.0)	0.003	32.0 (5.6)	32.5 (5.5)	<0.001	
Palafolls formula	29.6 (4.7)	29.9 (4.7)	< 0.001	38.7 (5.5)	38.9 (5.4)	<0.001	
Deurenberg formula	25.2 (6.5)	25.6 (6.5)	< 0.001	34.1 (7.1)	34.5 (7.1)	<0.001	
Body surface index	57.9 (7.9)	58.3 (7.9)	< 0.001	50.6 (8.1)	50.9 (8.1)	<0.001	
Normalized weight adjusted index	0.69 (1.37)	0.72 (1.37)	< 0.001	0.45 (1.37)	0.46 (1.37)	<0.001	
Body roundness index	3.3 (1.17)	3.4 (1.2)	< 0.001	2.7 (1.2)	2.8 (1.2)	0.004	
Body shape index	0.073 (0.006)	0.074 (0.006)	< 0.001	0.069 (0.006)	0.070 (0.006)	<0.001	
Visceral adiposity index	7.4 (6.4)	7.7 (6.6)	< 0.001	2.7 (1.6)	2.9(1.7)	0.193	
Dysfunctional adiposity index	0.90 (0.72)	0.92 (0.75)	< 0.001	0.69 (0.41)	0.72 (0.41)	0.101	
Conicity index	1.2 (0.1)	1.3 (0.1)	< 0.001	1.1 (0.1)	1.2 (0.1)	0.022	
METS-VF	6.2 (0.7)	6.4 (0.8)	< 0.001	5.5 (0.8)	5.7(0.8)	<0.001	
Waist triglyceride index	8.4 (0.6)	8.4 (0.6)	0.129	8.0 (0.5)	8.0 (0.5)	0.741	

CUN BAE Clínica Universitaria de Navarra body adiposity estimator; ECORE-BF Equation Córdoba for estimation of body fat.

Table IV shows the results of the multivariate analysis applying the multinomial logistic regression technique, in which the odds ratios with their 95% confidence intervals were established. Age, sex, and social class increased the risk of presenting high values in all the scales that assess

overweight and obesity. This risk increased with age and the lower the social class. It was also higher in men.

Tobacco consumption slightly increased this risk in all scales except BRI and METS-VF.

Table III: Prevalence of high values of the different indicators of	overweight and obesity according to tobacco con	sumption by sex.
---	---	------------------

	Men			Women		
	Non-smokers n=163920 %	Smokers n=82141 %	p-value	Non-smokers n=115727 %	Smokers n=56555 %	p-value
BMI modified obesity	17.8	17.9	<0.001	19.3	19.6	<0.001
Waist-to-height-ratio high	41.6	41.9	0.034	20.9	21.2	0.011
BMI obesity	19.8	19.9	< 0.001	16.5	17.0	< 0.001
CUN BAE obesity	52.4	52.8	< 0.001	48.2	48.8	< 0.001
ECORE-BF obesity	52.3	52.7	< 0.001	47.2	47.6	< 0.001
Relative fat mass obesity	34.9	35.5	0.046	48.3	52.8	< 0.001
Palafolls obesity	87.4	88.2	< 0.001	73.3	74.1	< 0.001
Deurenberg obesity	48.8	49.0	< 0.001	69.0	69.5	< 0.001
Body roundness index high	13.0	13.9	0.330	5.9	6.1	0.991
Body shape index high	15.9	16.9	< 0.001	12.8	13.1	0.957
Visceral adiposity index high	86.2	86.5	0.062	30.1	30.4	0.236
Dysfunctional adiposity index high	25.3	25.7	0.012	11.5	11.7	0.149
Conicity index high	21.7	22.4	< 0.001	10.3	10.5	0.813
Metabolic score for visceral fat high	8.6	8.8	0.088	1.3	1.5	0.036
Waist triglyceride index high	19.2	19.4	0.195	7.9	8.1	0.561

CUN BAE Clínica Universitaria de Navarra body adiposity estimator; ECORE-BF Equation Córdoba for estimation of body fat.

Table IV: Multinomial logistic regression.

	BMI obesity OR (95% CI)	BMI modified obesity OR (95% CI)	High WtHR OR (95% CI)	CUN BAE obesity OR (95% CI)	RFM obesity OR (95% CI)	Deurenberg obesity OR (95% CI)
18-29 years	1	1	1	1	1	1
30-39 years	1.10 (1.06-1.15)	1.19 (1.14-1.23)	1.09 (1.05-1.13)	1.91 (1.82-2.00)	1.07 (1.03-1.11)	2.97 (2.74-3.22)
40-49 years	1.41 (1.36-1.47)	1.61 (1.55-1.67)	1.28 (1.23-1.32)	4.18 (3.99-4.38)	1.28 (1.24-1.33)	10.72 (9.91-11.60)
50-59 years	1.98 (1.90-2.06)	2.32 (2.23-2.41)	1.65 (1.60-1.71)	9.07 (8.65-9.50)	1.69 (1.63-1.75)	38.56 (35.64-41.73)
60-69 years	3.1 (2.97-3.24)	3.64 (3.49-3.79)	2.33 (2.24-2.42)	19.76 (18.83-20.73)	2.27 (2.19-2.35)	118.99 (109.84-128.90)
Social class I	1	1	1	1	1	1
Social class II	1.45 (1.42-1.48)	1.55 (1.52-1.59)	1.22 (1.20-1.24)	1.36 (1.34-1.39)	1.25 (1.23-1.27)	1.30 (1.28-1.33)
Social class III	1.69 (1.63-1.76)	1.87 (1.80-1.95)	1.36 (1.32-1.40)	1.54 (1.49-1.58)	1.41 (1.37-1.45)	1.50 (1.45-1.54)
Female	1	1	1	1	1	1
Male	1.17 (1.15-1.19)	1.16 (1.15-1.18)	2.51 (2.47-2.54)	1.07 (1.06-1.09)	1.45 (1.44-1.46)	0.27 (0.26-0.27)
Smokers	1	1	1	1	1	1
Non-smokers	1.03 (1.02-1.05)	1.04 (1.02-1.06)	1.02 (1.00-1.03)	1.03 (1.02-1.05)	1.03 (1.01-1.04)	1.04 (1.03-1.06)
	Palafolls obesity	High BRI	High VAI	High DAI	High METS-VF	High WWI
	Palafolls obesity OR (95% CI)	High BRI OR (95% CI)	High VAI OR (95% CI)	High DAI OR (95% CI)	High METS-VF OR (95% CI)	High WWI OR (95% CI)
18-29 years	Palafolls obesity OR (95% CI)	High BRI OR (95% CI) 1	High VAI OR (95% CI)	High DAI OR (95% CI)	High METS-VF OR (95% CI)	High WWI OR (95% CI) 1
18-29 years 30-39 years	Palafolls obesity OR (95% Cl) 1 1.24 (1.16-1.33)	High BRI OR (95% CI) 1 1.06 (1.01-1.11)	High VAI OR (95% CI) 1 1.12 (1.07-1.18)	High DAI OR (95% CI) 1 1.16 (1.12-1.21)	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52)	High WWI OR (95% CI) 1 1.05 (1.01-1.10)
18-29 years 30-39 years 40-49 years	Palafolls obesity OR (95% Cl) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99)	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29)	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40)	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66)	High METS-VF OR (95% Cl) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97)	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44)
18-29 years 30-39 years 40-49 years 50-59 years	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43)	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75)	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92)	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59)	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02)	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08)
18-29 years 30-39 years 40-49 years 50-59 years 60-69 years	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43) 6.35 (5.97-6.77)	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75) 2.17 (2.05-2.29)	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92) 2.94 (2.80-3.08)	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59) 4.77 (4.58-4.98)	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02) 31.81 (28.82-35.12)	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08) 3.98 (3.79-4.18)
18-29 years 30-39 years 40-49 years 50-59 years 60-69 years Social class I	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43) 6.35 (5.97-6.77) 1 1	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75) 2.17 (2.05-2.29) 1	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92) 2.94 (2.80-3.08) 1	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59) 4.77 (4.58-4.98) 1	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02) 31.81 (28.82-35.12) 1 1	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08) 3.98 (3.79-4.18) 1 1
18-29 years 30-39 years 40-49 years 50-59 years 60-69 years Social class I Social class I	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43) 6.35 (5.97-6.77) 1 1.20 (1.17-1.22)	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75) 2.17 (2.05-2.29) 1 1.17 (1.14-1.35-1.49)	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92) 2.94 (2.80-3.08) 1 1.10 (1.08-1.12)	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59) 4.77 (4.58-4.98) 1 1.13 (1.10-1.15)	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02) 31.81 (28.82-35.12) 1 1.16 (1.12-1.21)	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08) 3.98 (3.79-4.18) 1 1.15 (1.12-1.18)
18-29 years 30-39 years 40-49 years 50-59 years 60-69 years Social class I Social class II Social class II	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43) 6.35 (5.97-6.77) 1 1.20 (1.17-1.22) 1.30 (1.25-1.34)	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75) 2.17 (2.05-2.29) 1 1.17 (1.14-1.35-1.49) 1.42 (1.35-1.49)	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92) 2.94 (2.80-3.08) 1 1.10 (1.08-1.12) 1.22 (1.18-1.26)	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59) 4.77 (4.58-4.98) 1 1.13 (1.10-1.15) 1.26 (1.22-1.31)	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02) 31.81 (28.82-35.12) 1 1.16 (1.12-1.21) 1.44 (1.34-1.54)	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08) 3.98 (3.79-4.18) 1 1.15 (1.12-1.18) 1.38 (1.32-1.44)
18-29 years 30-39 years 40-49 years 50-59 years 60-69 years Social class I Social class II Social class III Female	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43) 6.35 (5.97-6.77) 1 1.20 (1.17-1.22) 1.30 (1.25-1.34) 1 2.42 (5.0.57)	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75) 2.17 (2.05-2.29) 1 1.17 (1.14-1.35-1.49) 1.42 (1.35-1.49) 1 2.00 (200 0.01)	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92) 2.94 (2.80-3.08) 1 1.10 (1.08-1.12) 1.22 (1.18-1.26) 1	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59) 4.77 (4.58-4.98) 1 1.13 (1.10-1.15) 1.26 (1.22-1.31) 1 1	High METS-VF OR (95% Cl) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02) 31.81 (28.82-35.12) 1 1.16 (1.12-1.21) 1.44 (1.34-1.54) 1 2.55 (1.0.2.55)	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08) 3.98 (3.79-4.18) 1 1.15 (1.12-1.18) 1.38 (1.32-1.44) 1 2 0 0 0 1 0 0 1 0 0 0
18-29 years 30-39 years 40-49 years 50-59 years 60-69 years Social class I Social class II Social class III Female Male	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43) 6.35 (5.97-6.77) 1 1.20 (1.17-1.22) 1.30 (1.25-1.34) 1 2.43 (2.39-2.47)	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75) 2.17 (2.05-2.29) 1 1.17 (1.14-1.35-1.49) 1.42 (1.35-1.49) 1 2.28 (2.23-2.34)	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92) 2.94 (2.80-3.08) 1 1.10 (1.08-1.12) 1.22 (1.18-1.26) 1 15.28 (15.04-15.53)	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59) 4.77 (4.58-4.98) 1 1.13 (1.10-1.15) 1.26 (1.22-1.31) 1 2.54 (2.50-2.59)	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02) 31.81 (28.82-35.12) 1 1.16 (1.12-1.21) 1.44 (1.34-1.54) 1 6.75 (6.46-7.06)	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08) 3.98 (3.79-4.18) 1 1.15 (1.12-1.18) 1.38 (1.32-1.44) 1 2.69 (2.64-2.75)
18-29 years 30-39 years 40-49 years 50-59 years 60-69 years Social class I Social class II Social class III Female Male Smokers	Palafolls obesity OR (95% CI) 1 1.24 (1.16-1.33) 1.87 (1.76-1.99) 3.22 (3.03-3.43) 6.35 (5.97-6.77) 1 1.20 (1.17-1.22) 1.30 (1.25-1.34) 1 2.43 (2.39-2.47) 1 1	High BRI OR (95% CI) 1 1.06 (1.01-1.11) 1.23 (1.17-1.29) 1.67 (1.58-1.75) 2.17 (2.05-2.29) 1 1.17 (1.14-1.35-1.49) 1.42 (1.35-1.49) 1.228 (2.23-2.34) 1	High VAI OR (95% CI) 1 1.12 (1.07-1.18) 1.34 (1.28-1.40) 2.79 (2.67-2.92) 2.94 (2.80-3.08) 1 1.10 (1.08-1.12) 1.22 (1.18-1.26) 1 15.28 (15.04-15.53) 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	High DAI OR (95% CI) 1 1.16 (1.12-1.21) 1.60 (1.54-1.66) 2.49 (2.40-2.59) 4.77 (4.58-4.98) 1 1.13 (1.10-1.15) 1.26 (1.22-1.31) 1 2.54 (2.50-2.59) 1	High METS-VF OR (95% CI) 1 1.45 (1.38-1.52) 2.83 (2.69-2.97) 7.57 (7.14-8.02) 31.81 (28.82-35.12) 1 1.16 (1.12-1.21) 1.44 (1.34-1.54) 1 6.75 (6.46-7.06) 1	High WWI OR (95% CI) 1 1.05 (1.01-1.10) 1.32 (1.26-1.44) 1.99 (1.91-2.08) 3.98 (3.79-4.18) 1 1.15 (1.12-1.18) 1.38 (1.32-1.44) 1 2.69 (2.64-2.75) 1

BMI body mass index.; WtHR waist to height ratio; CUN BAE Clínica Universitaria de Navarra body adiposity estimator; ECORE-BF Equation Córdoba for estimation of body fat; RFM relative fat mass; BRI body roundness index; VAI visceral adiposity index; DAI dysfunctional adiposity index; METS-VF metabolic score for visceral fat; WWI waist weight index.

Discussion

There is an increase in the mean values and in the prevalence of high values in the scales that determine overweight and obesity. High values are more frequent in men, with increasing age, in smokers, and in persons belonging to the most disadvantaged social levels (social class III).

A study by the Spanish food safety and nutrition agency (AESAN)²⁹ carried out in 2021 shows that in both sexes the prevalence of obesity increases with age, as found in our work. A study carried out in Spain by the Statista Research Department³⁰ expresses the same view.

In our study, male sex increases the risk of presenting high values in all the scales that assess overweight and obesity. These data coincide with those found in the aforementioned Statista study³⁰. Something similar was found when we consulted the prevalence of obesity in Spain according to data from the Ministry of Health³¹, revealing that the prevalence is higher among men in all the autonomous communities in Spain. This situation is not only observed in our country, as global prevalence data in adults by sex in the world also show higher figures in men³².

According to data from the 2017 Spanish national health survey published National Institute of Statistics (INE)³³, obesity presents an important and significant social disparity. Patterns of prevalence variation with social class are particularly notable in women, ranging from 7.3% in the most favored social class (class I) to 24% in the most disadvantaged social class (class III), confirming our data. A study carried out in Colombia³⁴ assessed the effect of socioeconomic level on the prevalence of overweight and obesity in women, concluding that the prevalence of overweight and obesity is unequal and affects people of lower socioeconomic levels more. Another Spanish study published in *Nutrición Clínica y Dietética Hospitalaria*³⁵ expressed itself in similar terms.

The prevalence of overweight and obesity in our study was higher on all scales in the group of smokers.

According to research published in the British Medical Journal and funded by Cancer Research UK, an increase in body mass index, body fat percentage, and waist circumference are linked to both an increased risk of being a smoker and a higher number of cigarettes smoked daily³⁶. A review conducted in Chile³⁷ revealed that although smoking has been associated with a low body mass index (BMI), heavy smokers are more likely to develop obesity, and 35-65% of smokers seeking smoking cessation treatment are overweight or obese.

By way of strengths, we would highlight the enormous sample size analyzed, which exceeds 418,000 workers, and the large number of scales assessing excess weight that were used.

The main limitation is that the people included in the study are aged between 18 and 69 years (working age), so the results may not be extrapolated to the general population.

Conclusions

All the sociodemographic variables analyzed –sex, age, and social class– influence the appearance of high values in the scales that assess overweight and obesity.

Tobacco consumption also had an influence, although less than the previous variables, on the appearance of high values in almost all the scales that assess overweight and obesity, except BRI and METS-VF.

Conflict of Interest

The authors declared that there is no conflict of interest.

References

1. Izquierdo-Torres E, Hernández-Oliveras A, Lozano-Arriaga D, Zarain-Herzberg Á. Obesity, the other pandemic: linking diet and carcinogenesis by epigenetic mechanisms. J Nutr Biochem. 2022 Oct;108:109092. doi: 10.1016/j.jnutbio.2022.109092.

2. Valenzuela PL, Carrera-Bastos P, Castillo-García A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic diseases. Nat Rev Cardiol. 2023 Jul;20(7):475-494. doi: 10.1038/s41569-023-00847-5

3. Belladelli F, Montorsi F, Martini A. Metabolic syndrome, obesity and cancer risk. Curr Opin Urol. 2022 Nov 1;32(6):594-597. doi: 10.1097/ MOU.000000000001041.

4. Niemiro GM, Rewane A, Algotar AM. Exercise and Fitness Effect On Obesity. 2023 May 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. PMID: 30969715.

5. González-Pérez B, Muñoz-Rocha M, Segura-Chico M, Magaña-Torres MT, Carrillo-Aguiar LA, Salas.Flor R. Trastomos funcionales gastrointestinales en niños con obesidad en atención primaria. AJHS 2022;37 (5): 88-92 doi: 10.3306/AJHS.2022.37.05.88 6. Fulton M, Srinivasan VN. Obesity, Stigma And Discrimination. 2023 Mar 13. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. PMID: 32119458.

7. Vicente-Herrero MT, Ramírez MV, Capdevila L, Partida-Hanon A, Reinosos-Barbero L, López-González AA. Lifestyle, overweight and obesity in spanish workers: related AJHS 2022 37 (4): 135-43 doi: 10.3306/AJHS.2022;37.04.135

8. López-González AA, Tomás-Gil P, Coll-Villalonga JL, Martí-Literas P, González-San Miguel H, Ramírez-Manent JI. Correlation between overweight and obesity scales and blood pressure values in 418.343 Spanish workers. AJHS 2023;38 (3): 44-51 doi: 10.3306/ AJHS.2023.38.03.44

9. Han MK, Ye W, Wang D, White E, Arjomandi M, Barjaktarevic IZ, Brown SA, et al. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. N Engl J Med. 2022 Sep 29;387(13):1173-1184. doi: 10.1056/NEJMoa2204752.

10. Li S, Liu Z, Joseph P, Hu B, Yin L, Tse LA, et al. Modifiable risk factors associated with cardiovascular disease and mortality in China:

a PURE substudy. Eur Heart J. 2022 Aug 7;43(30):2852-2863. doi: 10.1093/eurheartj/ehac268.

11. Jasper RA, Chen PH, Patel R, Joseph S, Miller SD, Hutfless S. Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010-2019. JGH Open. 2023 Mar 31;7(4):291-298. doi: 10.1002/jgh3.12893.

12. Eng L, Brual J, Nagee A, Mok S, Fazelzad R, Chaiton M, et al. Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. ESMO Open. 2022 Dec;7(6):100605. doi: 10.1016/j.esmoop.2022.100605.

13. Mohebbi V, Lagrava R, Aramayo A, Liceras C, Apaza B.Results of a health intervention program in 1094 bolivian mining workers. AJHS 2022; 37 (1): 48-51 doi: 10.3306/AJHS.2022.37.01.48

14. Molina-Luque R, Yañez AM, Bennasar-Veny M, Romero-Saldaña M, Molina-Recio G, López-González ÁA. A Comparison of Equation Córdoba for Estimation of Body Fat (ECORE-BF) with Other Prediction Equations. Int J Environ Res Public Health. 2020 Oct 29;17(21):7940. doi: 10.3390/ijerph17217940.

15. Senkus KE, Crowe-White KM, Locher JL, Ard JD. Relative fat mass assessment estimates changes in adiposity among female older adults with obesity after a 12-month exercise and diet intervention. Ann Med. 2022 Dec;54(1):1160-1166. doi: 10.1080/07853890.2022.2067352.

16. López-González AA, Jover AM, Martínez CS, Artal PM, Bote SA, Jané BA, et al. The CUN-BAE, Deurenberg Fat Mass, and visceral adiposity index as confident anthropometric indices for early detection of metabolic syndrome components in adults. Sci Rep. 2022 Sep 15;12(1):15486. doi: 10.1038/s41598-022-19343-w.

17. López-González AA, Ramírez Manent JI, Vicente-Herrero MT, García Ruiz E, Albaladejo Blanco M, López Safont N. [Prevalence of diabesity in the Spanish working population: influence of sociodemographic variables and tobacco consumption]. An Sist Sanit Navar. 2022 Apr 27;45(1):e0977. Spanish. doi: 10.23938/ASSN.0977.

18. Feng L, Chen T, Wang X, Xiong C, Chen J, Wu S, et al. Metabolism Score for Visceral Fat (METS-VF): A New Predictive Surrogate for CKD Risk. Diabetes Metab Syndr Obes. 2022 Jul 29;15:2249-2258. doi: 10.2147/DMSO.S370222.

19. Shen X, Chen Y, Chen Y, Liang H, Li G, Hao Z. Is the METS-IR Index a Potential New Biomarker for Kidney Stone Development? Front Endocrinol (Lausanne). 2022 Jul 14;13:914812. doi: 10.3389/fendo.2022.914812.

20. Mancio J, Pinheiro M, Ferreira W, Carvalho M, Barros A, Ferreira N, et al. Gender differences in the association of epicardial adipose tissue and coronary artery calcification: EPICHEART study: EAT and coronary calcification by gender. Int J Cardiol. 2017 Dec 15;249:419-425. doi: 10.1016/j.ijcard.2017.09.178.

21. Doménech-Asensi G, Gómez-Gallego C, Ros-Berruezo G, García-Alonso FJ, Canteras-Jordana M. Critical overview of current anthropometric methods in comparison with a new index to make early detection of overweight in Spanish university students: the normalized weight-adjusted index. Nutr Hosp. 2018 Mar 1;35(2):359-367. English. doi: 10.20960/nh.1189.

22. Nagayama D, Fujishiro K, Watanabe Y, Yamaguchi T, Suzuki K, Saiki A, et al. A Body Shape Index (ABSI) as a Variant of Conicity Index Not Affected by the Obesity Paradox: A Cross-Sectional Study Using Arterial Stiffness Parameter. J Pers Med. 2022 Dec 5;12(12):2014. doi: 10.3390/jpm12122014.

23. Zhang Y, Gao W, Ren R, Liu Y, Li B, Wang A, et al. Body roundness index is related to the low estimated glomerular filtration rate in Chinese population: A cross-sectional study. Front Endocrinol (Lausanne). 2023 Mar 28;14:1148662. doi: 10.3389/fendo.2023.1148662.

24. Qin Z, Jiang L, Sun J, Geng J, Chen S, Yang Q, et al. Higher visceral adiposity index is associated with increased likelihood of abdominal aortic calcification. Clinics (Sao Paulo). 2022 Sep 24;77:100114. doi: 10.1016/j.clinsp.2022.100114.

25. Vicente-Herrero MT, Egea Sancho M, Ramírez Íñiguez de la Torre MV, López González ÁA. Relación de los índices de adiposidad visceral (VAI) y disfuncional (DAI) con parámetros de obesidad [Visceral adiposity index (VAI) and dysfunctional adiposity index (DAI). Relationship with obesity parameters]. Semergen. 2023 Apr 17;49(6):101965. Spanish. doi: 10.1016/j.semerg.2023.101965.

26. Martins CA, do Prado CB, Santos Ferreira JR, Cattafesta M, Dos Santos Neto ET, Haraguchi FK, et al. Conicity index as an indicator of abdominal obesity in individuals with chronic kidney disease on hemodialysis. PLoS One. 2023 Apr 19;18(4):e0284059. doi: 10.1371/ journal.pone.0284059.

27. Park Y, Kim NH, Kwon TY, Kim SG. A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality. Sci Rep (2018) 8(1):16753. doi: 10.1038/s41598-018-35073-4

28.Domingo-Salvany A, Bacigalupe A, Carrasco JM, Espelt A, Ferrando J, Borrell C, et al. Propuestas de clase social neoweberiana y neomarxista a partir de la Clasificación Nacional de Ocupaciones 2011. Gac Sanit. 2013 May-Jun;27(3):263-72 doi: 10.1016/j.gaceta.2012.12.009.

29. Evaluación y seguimiento de la Estrategia NAOS: conjunto mínimo de indicadores. Agencia Española de Seguridad Alimentaria y Nutrición. Ministerio de Consumo. Madrid, 2021. http://www.aecosan.msssi.gob.es/AECOSAN/web/nutricion/subseccion/indicadores.htm

30. Obesidad: prevalencia por género y edad España 2017 | Statista

31. Ministerio de Sanidad - Portal Estadístico del SNS - Porcentaje de personas con obesidad, por sexo según comunidad autónoma

32. Obesidad y sobrepeso: prevalencia 2020-2035 | Statista

33. ENSE2017_notatecnica.pdf (sanidad.gob.es)

34. Montero-López M, Santamaría-Ulloa C, Bekelman T, Arias-Quesada J, Corrales-Calderón J, Jackson-Gómez M, et al. Determinantes sociales de la salud y prevalencia de sobrepeso-obesidad en mujeres urbanas, según nivel socioeconómico. Hacia Promoc. Salud [Internet]. 2021;26(2):192-207.

35. Medina FX, Aguilar A, Solé-Sedeño JM. Aspectos sociales y culturales sobre la obesidad: reflexiones necesarias desde la salud pública. Nutr. clín. diet. hosp. 2014; 34(1):67-71 DOI: 10.12873/341medina

36. Domer TE, Brath H, Kautzky-Willer A. Sex-specific trends in smoking prevalence over seven years in different Austrian populations: results of a time-series cross-sectional analysis. BMJ Open. 2020 Sep 9;10(9):e035235. doi: 10.1136/bmjopen-2019-035235.

37. Escaffi MJ, Ada Cuevas M, Vergara K, Rodrigo Alonso K. Tabaco y peso corporal. Rev. Chil. Enferm. Respir 2017; 33(3): 249-51.